Skip to search formSkip to main contentSkip to account menu

PF-04691502

Known as: PI3K/mTOR Kinase Inhibitor PF-04691502 
An agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
BackgroundThis phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and… 
Highly Cited
2013
Highly Cited
2013
SummaryPurpose To determine the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, and preliminary… 
Highly Cited
2013
Highly Cited
2013
Purpose: Phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway activation is often associated with… 
2013
2013
PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide) mutations can help predict the antitumor activity of… 
Highly Cited
2011
Highly Cited
2011
Deregulation of the phosphoinositide 3-kinase (PI3K) signaling pathway such as by PTEN loss or PIK3CA mutation occurs frequently…